Notification from the National Centre for Research and Development that the CT-01 project has not been selected for funding for the second phase of this project

Current report No. 7/2024

Date of preparation: 06.03.2024

Subject: Notification from the National Centre for Research and Development that the CT-01 project has not been selected for funding for the second phase of this project

Legal basis: Article 17(1) MAR - confidential information.

With reference to current report 55/2023 of 13 November 2023, the Management Board of Captor Therapeutics S.A., based in Wrocław (the "Company"), announces that the Company has received a letter from the National Centre for Research and Development ("NCBR") informing that Project CT-01 (Discovery and development of a drug candidate for the treatment of hepatocellular carcinoma to eliminate cancer stem cells by induced degradation of an oncogenic transcription factor) (the "Project") has not been selected for funding for the second phase of this Project.

The information was provided in connection with the Company's application for funding of the second phase of the Project from 1 January 2024 (during the extended Project period until 31 March 2026) in the amount of PLN 6 766 157,95.

The Company has reviewed the information from NCBR and does not agree with the grounds for refusal of funding. According to the information from NCBR, the Project has met 10 out of 11 criteria for co-financing, and the unmet criterion relates in particular to certain elements of the proposed Project budget.

The Company intends to file a protest to NCBR in order to re-check the application in terms of meeting the project selection criteria.

The Company will inform for further proceedings as required by law.